Assets Sale, Donations, Clinical Research Data, IPO Filing, and Earnings Release Schedules - Analyst Notes on HSBC, BP, GSK,

   Assets Sale, Donations, Clinical Research Data, IPO Filing, and Earnings
      Release Schedules - Analyst Notes on HSBC, BP, GSK, Shell and BAT

Editor Note: For more information about this release, please scroll to bottom.

  PR Newswire

  LONDON, June 27, 2014

LONDON, June 27, 2014 /PRNewswire/ --

Today, Earnings Review released its analysts' notes regarding HSBC Holdings
Plc (LON: HSBA), BP Plc (LON: BP), GlaxoSmithKline Plc (LON: GSK), Royal Dutch
Shell Plc (LON: RDSA) and British American Tobacco Plc (LON: BATS). Private
wealth members receive these notes ahead of publication. To reserve
complementary membership, limited openings are available at: . HSBC Holdings Plc Analyst Notes On
June 24, 2014, HSBC Holdings Plc (HSBC) announced that its indirect
wholly-owned subsidiary HSBC Private Bank (Suisse) SA has agreed to sell a
portfolio of its private banking assets in Switzerland to LGT Bank
(Switzerland) Ltd, a wholly-owned subsidiary of the LGT Group Foundation. HSBC
informed that the portfolio had $12.5 billion in assets under management as at
December 31, 2013. HSBC expects the transaction to be completed in Q4 2014.
The full analyst notes on HSBC are available to download free of charge at: BP Plc Analyst Notes On
June 24, 2014, BP Plc (BP) announced that it has made a $2.5 million donation
to the 2015 Chicago Architecture Biennial and will serve as the major sponsor
of the three-month long exhibition. Commenting on the development, John Mingé,
BP America Chairman and President, said, "BP has a long history of supporting
programs, events and institutions that make Chicago great, and we're proud to
sponsor this celebration of the city's significant contribution to world
architecture." The first-ever Chicago Architecture Biennial, to be held from
October 1, 2015 through January 3, 2016, will include a number of exhibitions
and educational programs featuring many of the world's leading architects. The
full analyst notes on BP are available to download free of charge at: GlaxoSmit hKline Plc Analyst
Notes On June 14, 2014, GlaxoSmithKline Plc (GSK) presented new data from
secondary analyses of four randomised phase III studies at the 74th Scientific
Sessions of the American Diabetes Association (ADA) in San Francisco. The new
data showed that patients enrolled in the studies who remained on
Tanzeum/Eperzan (albiglutide), a once-weekly glucagon-like peptide (GLP-1)
receptor agonist, continued to show blood glucose lowering at three years,
consistent with results at the one year or 52 week primary endpoint. Vlad
Hogenhuis, Senior Vice-President and Head, Cardiovascular, Metabolic and
Neurosciences Franchise, GSK, said, "While many phase III trials in type 2
diabetes are typically six months in duration, we set out to assess
weekly-administered albiglutide for up to three years. We are proud to be able
to present these data which further characterize the efficacy and safety
profile of albiglutide." The full analyst notes on GSK are available to
download free of charge at:
Royal Dutch Shell Plc Analyst Notes On June 18, 2014, Royal Dutch Shell Plc
(Shell) announced that its wholly-owned subsidiary Shell Midstream Partners,
L.P. has filed for an Initial Public Offering (IPO) with the U.S. Securities
and Exchange Commission (SEC). According to a Reuters report dated June 18,
2014, the proposed IPO seeks to raise up to $750 million and the offer
proceeds will be used to acquire stakes in Shell's other pipelines. Shell
Midstream Partners intends to apply to list the common units on the New York
Stock Exchange under the ticker symbol "SHLX". According to the Company, the
offering is expected to occur in the second half of this year. Shell Midstream
Partners was formed as a vehicle to own, operate, develop and acquire
pipelines and other midstream assets. The full analyst notes on Shell are
available to download free of charge at: British American Tobacco
Plc Analyst Notes As per the Financial Calendar available at British American
Tobacco Plc's (BAT) official website, the Company will publish its Half-yearly
Report on July 30, 2014. In an announcement dated April 30, 2014, the Company
had informed that the half-yearly report will also include announcement of
declaration of interim dividend. In Q1 2014, the Company had reported a
decline of 1.2% YoY in cigarette volumes, as growth in markets including
Bangladesh, Pakistan, Indonesia, Japan and the GCC was offset by lower volumes
in Russia and Poland. Group revenue for Q1 2014 grew by 2% at constant rates
of exchange, indicating towards lower volume and the timing of price
increases, in comparison to Q1 2013. The full analyst notes on BAT are
available to download free of charge at: =============== EDITOR'S
NOTES: =============== 1. This is not company news. We are an independent
source and our views do not reflect the companies mentioned. 2. Information in
this release is produced on a best efforts basis by Rohit Tuli, a CFA
charterholder. The content is then further fact checked and reviewed by an
outsourced research provider. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us below. 3.
This information is submitted as a net-positive to companies mentioned, to
increase awareness for mentioned companies to our subscriber base and the
investing public. 4. If you wish to have your company covered in more detail
by our team, or wish to learn more about our services, please contact us at
pubco [at] . 5. For any urgent concerns or
inquiries, please contact us at compliance [at] .
6. Are you a public company? Would you like to see similar coverage on your
company? Send us a full investors' package to research [at] for consideration. COMPLIANCE PROCEDURE Content is
researched, written and reviewed on a best-effort basis. This document,
article or report is prepared and authored by Earnings Review, represented by
Rohit Tuli, CFA. An outsourced research services provider has only reviewed
the information provided by Earnings Review in this article or report
according to the procedures outlined by Earnings Review. Earnings Review is
not entitled to veto or interfere in the application of such procedures by the
outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE Earnings Review makes no warranty, expressed or implied,
as to the accuracy or completeness or fitness for a purpose (investment or
otherwise), of the information provided in this document. This information is
not to be construed as personal financial advice. Readers are encouraged to
consult their personal financial advisor before making any decisions to buy,
sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED
Earnings Review is not responsible for any error which may be occasioned at
the time of printing of this document or any error, mistake or shortcoming. No
liability is accepted by Earnings Review whatsoever for any direct, indirect
or consequential loss arising from the use of this document. Earnings Review
expressly disclaims any fiduciary responsibility or liability for any
consequences, financial or otherwise arising from any reliance placed on the
information in this document. Earnings Review does not (1) guarantee the
accuracy, timeliness, completeness or correct sequencing of the information,
or (2) warrant any results from use of the information. The included
information is subject to change without notice. CFA® and Chartered Financial
Analyst® are registered trademarks owned by CFA Institute.

Contact: CONTACT PERSON: Adam Redford, CONTACT PHONE: +1-852-8191-3972
Press spacebar to pause and continue. Press esc to stop.